A Phase 1b/2a Study of Velinotamig in Adults With Relapsed/Refractory ITP and wAIHA (clinicaltrials.gov) - Aug 1, 2026 - P1/2 | N=72 | Not yet recruiting | Sponsor: Cullinan Therapeutics Inc.
New P1/2 trial • Anemia • Autoimmune Hemolytic Anemia • Hematological Disorders • Immune Thrombocytopenic Purpura • Immunology • Thrombocytopenia • Thrombocytopenic Purpura
|